INTRODUCTION
HEMODIALYSIS (HD) is the routine renal replacement therapy for more than 300,000 patients in the United States who have reached end-stage renal disease. The goals of HD are straightforward and include restoring the body's intracellular and extracellular fluid environment and accomplishing solute balance by either removal from the blood into the dialysate or from the dialysate into the blood. Optimal care of the patient receiving long-term HD requires broad knowledge of the HD technique and appropriate prescription according to patient-and devicedependent variables. This Core Curriculum aims to provide a comprehensive but also concise description of HD technique and prescription. Clinically relevant practical information is provided in appropriate sections.
HEMODIALYSIS TECHNIQUES

Components
Blood circuit
• 
Capacity for UF (fluid removal)
UF coefficient (KUF).
• KUF determines quantity of pressure that must be exerted across dialysis membrane (transmembrane pressure) to generate a given volume of ultrafiltrate per unit time • High-flux membranes are defined as having UF coefficient Ͼ 15 mL/h/mm Hg • KUF is dialyzer specific and determined by membrane composition, surface area, and geometry Flux characteristics.
• Low flux Ⅲ KUF Ͻ 15 mL/h/mm Hg or ␤ 2 -microglobulin clearance Ͻ 10 mL/min
• High flux: Ⅲ KUF Ͼ 15 mL/h/mm Hg or ␤ 2 -microglobulin clearance Ͼ 20 mL/min; KoA Ͼ 450 mL/min Ⅲ Subgroup analysis of the HEMO Study suggested cardiovascular survival advantage in patients randomized to high-flux arm of study Net pressure gradient.
• Difference between blood and dialysate hydraulic pressures (calculated as arithmetic mean of inlet and outlet pressures of dialyzer) Transmembrane pressure.
• Effective pressure required to achieve a particular fluid loss (transmembrane pressure ϭ desired weight loss/[UF coefficient ϫ dialysis time]) • Can be varied by changing pressure in blood and dialysate compartments and therefore can selectively determine UF rate for a given dialyzer UF rate prescription.
• Goal is to achieve estimated dry weight (lowest weight a patient can tolerate without development of signs or symptoms of intravascular hypovolemia) • Tolerance determined by vascular refilling • On-line monitoring of blood volume changes may help prescription • UF modeling may reduce intradialytic complication
Length of treatment
• Clearance of a high-molecular-weight solute can be increased by lengthening HD treatment • Increasing time decreases low-molecularweight solute removal and does not result in equivalent increases in low-molecular-weight solute removal (diminishing return)
Flow
Blood flow (Qb).
• Flow-limited mass transfer and membranelimited mass transfer (defined by specific dialyzer and solute being measured) together determine clearance characteristics • As blood and dialysate flow rates increase, resistance and turbulence within dialyzer also increase
• Efficacy of vascular access may affect solute clearance due to recirculation (stenosis at venous or arterial anastomoses or midgraft): Ⅲ Recirculation can be measured by simultaneous measurement of a solute (usually blood urea nitrogen) from arterial line and from a peripheral blood source-this method is inaccurate due to "cardiopulmonary recirculation" and worse during high-efficiency HD; it is of historical curiosity and should not be performed routinely Ⅲ Slow-flow method is routinely used to measure recirculation Ⅲ Newer methods, such as indicator technique, demonstrate that recirculation is rare during HD Dialysate flow (Qd).
• Practical upper limit of effective dialysate flow is twice blood flow rate, beyond which gain in solute removal is minimal • High flow rates should be confined to blood flows Ͼ 300 mL/min
Anticoagulation
• Interaction of plasma with dialysis membrane leads to activation of clotting cascade • Dialyzer thrombogenicity is determined by:
Ⅲ Dialysis membrane composition Ⅲ Surface charge, area, and configuration Ⅲ Rate of blood flow through dialyzer Ⅲ UF rate (due to hemoconcentration) Ⅲ Length, diameter, and composition of blood lines Ⅲ Patient-specific variables • Most common anticoagulant is systemic heparin: Ⅲ Easy to administer Ⅲ Low cost Ⅲ Short biological half-life Ⅲ Bolus and/or incremental administration during HD; occasionally regional administration or no heparin (saline flushes) Ⅲ In routine clinical practice, intensity of anticoagulation is not measured; anticoagulant therapy can be used under some circumstances (ϳ50% above baseline) • Low-molecular-weight heparin:
Ⅲ Limited data 
Measurement of dialysis dose
Urea reduction ratio.
• The fractional decrease in blood urea nitrogen during a single HD • Simple to calculate
• Assumes constant urea volume and no disequilibrium • Does not include effects of UF • K/DOQI guidelines suggest urea reduction ratio at least 65% Single-compartment urea kinetics.
• Most commonly applied method for quantifying HD in clinical practice • Two blood urea nitrogen method • Equilibrated Kt/V to account for rebound Multiple-compartment urea kinetics.
• Developed to account for solute disequilibrium:
to its complexity Continuous equivalent of urea clearance.
• Allows comparison of dialysis dose between different modalities • No standard for adequacy limits • Difficult to calculate Normalized Kt/V.
• Not practical Standard Kt/V.
• Measures and compares dialysis dose regardless of schedule Solute removal index (SRI).
• No standards of adequacy for SRI • Lower than blood-based Kt/V Dialysate Dialysate characteristics influence the final concentration of blood solute, intermediary protein, carbohydrate, and lipid metabolism and affect systemic vasomotor tone, cardiac contractility and rhythm, pulmonary gas exchange, and bone turnover.
Composition
Sodium.
• "Standard" to have a dialysate sodium concentration similar to plasma sodium concentration • Use higher dialysate sodium or sodium modeling in patients prone to intradialytic hypotension
Potassium.
• Efficacy of intradialytic potassium removal is highly variable, difficult to predict, and influenced by dialysis-specific and patientspecific factors • Dialysate potassium concentration of 1-3 mEq/L is used in most patients • Low dialysate potassium concentrations should be used with caution (due to association between use of low dialysate potassium with sudden cardiac death) Buffer.
• Correction of acidosis is largely achieved by using a dialysate with higher concentration of alkaline equivalents than are present in blood, promoting flux of base from dialysate into blood • Base transfer across dialysis membrane can be achieved using either bicarbonate-or acetate-containing dialysate: Hemodialysis Membrane
